Jul 18, 2024 / 11:00AM GMT
Joachim Kreuzburg - Sartorius AG - Chairman of the Executive Board, Chief Executive Officer
Welcome everyone, and thank you for dialing in at this little bit unusual time for our call on quarterly results. Obviously, this is because we pulled the publication forward in the context of our decision to de-risk our guidance and therefore ad hoc these news in the format of an ad hoc announcement just a little bit earlier today.
I would like to walk you through the highlights and the most important points for H1 of the Sartorius group, that largely also are relevant for Sartorius Stedim Biotech. I will then hand over to Florian, our CFO, who will walk you through the numbers in more detail.
Thereafter, I will talk a little bit more in detail about the revised guidance for full-year 2024. Then we will hand over to Rene who will talk about Sartorius Stedim Biotech for H1 as well as outlook. So as we also said for Q1, one can clearly say that we still see a very mixed picture regarding market conditions and how this reflects then in our numbers.
First of all, we have to say we did
Q2 2024 Sartorius AG and Sartorius Stedim Biotech SA Earnings Call Transcript
Jul 18, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers